Soligenix Registered - Meinungen zu dieser Aktie? (Seite 21)
eröffnet am 04.11.16 16:25:57 von
neuester Beitrag 08.01.24 14:33:39 von
neuester Beitrag 08.01.24 14:33:39 von
Beiträge: 341
ID: 1.240.929
ID: 1.240.929
Aufrufe heute: 0
Gesamt: 32.133
Gesamt: 32.133
Aktive User: 0
ISIN: US8342235053 · WKN: A3D506 · Symbol: SNGX
0,4048
USD
+2,98 %
+0,0117 USD
Letzter Kurs 02:00:00 NYSE
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 13,110 | +38,44 | |
| 1,1514 | +30,84 | |
| 0,9150 | +21,84 | |
| 1,2100 | +21,00 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 5,0300 | -19,90 | |
| 36,70 | -22,87 | |
| 2,5500 | -25,22 | |
| 1,3500 | -26,63 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
dann fällt eine Phase 3 Studie weg ......damn.....
Ich hab für 1,08 aufgedoppelt
gehts in pennystock rein? mal sehen was die amis sagen
Hab paar Stücke nachgekauft.
Antwort auf Beitrag Nr.: 66.160.213 von coronus am 22.12.20 13:05:27ja aber typisch für biotec. jedenfalls günstig jetzt. aber wahrscheinlich bleibt das auf dem niveau ne weile. 
Trading Spotlight
Antwort auf Beitrag Nr.: 66.160.051 von Zunrise am 22.12.20 12:53:10Ups übersehen...aber auch etwas übertrieben der Abschlag
Bin zu 1,40 mal raus. Das war mein letzter nachkaufkurs. Hoffe das war die richtige Entscheidung
Antwort auf Beitrag Nr.: 66.159.841 von sneakee am 22.12.20 12:39:40hier der link
https://finance.yahoo.com/news/soligenix-announces-topline-r…
https://finance.yahoo.com/news/soligenix-announces-topline-r…
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Company to Host Investor Conference Call Today at 8:30AM EST
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results for its pivotal Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity) trial evaluating SGX942 (dusquetide) in the treatment of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) receiving chemoradiation. The study enrolled 268 patients randomized 1:1 to receive either SGX942 or placebo. The primary endpoint of median duration of SOM did not achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group. Despite this clinically meaningful improvement, the variability in the distribution of the data yielded a p-value that was not statistically significant.
Other secondary endpoints supported the biological activity of dusquetide, including a statistically significant 50% reduction in the duration of SOM in the per-protocol population, which decreased from 18 days in the placebo group to 9 days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial. Similarly, incidence of SOM also followed this biological trend as seen in the Phase 2 study, decreasing by 16% in the SGX942 treatment group relative to the placebo group in the per-protocol population. The per-protocol population was defined as the population receiving a minimum of 55 Gy radiation and at least 10
Company to Host Investor Conference Call Today at 8:30AM EST
PRINCETON, N.J., Dec. 22, 2020 /PRNewswire/ -- Soligenix, Inc. (NASDAQ: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today preliminary top-line results for its pivotal Phase 3 DOM-INNATE (Dusquetide treatment in Oral Mucositis – by modulating INNATE Immunity) trial evaluating SGX942 (dusquetide) in the treatment of severe oral mucositis (SOM) in patients with head and neck cancer (HNC) receiving chemoradiation. The study enrolled 268 patients randomized 1:1 to receive either SGX942 or placebo. The primary endpoint of median duration of SOM did not achieve the pre-specified criterion for statistical significance (p≤0.05); although biological activity was observed with a 56% reduction in the median duration of SOM from 18 days in the placebo group to 8 days in the SGX942 treatment group. Despite this clinically meaningful improvement, the variability in the distribution of the data yielded a p-value that was not statistically significant.
Other secondary endpoints supported the biological activity of dusquetide, including a statistically significant 50% reduction in the duration of SOM in the per-protocol population, which decreased from 18 days in the placebo group to 9 days in the SGX942 treatment group (p=0.049), consistent with the findings in the Phase 2 trial. Similarly, incidence of SOM also followed this biological trend as seen in the Phase 2 study, decreasing by 16% in the SGX942 treatment group relative to the placebo group in the per-protocol population. The per-protocol population was defined as the population receiving a minimum of 55 Gy radiation and at least 10
Antwort auf Beitrag Nr.: 66.159.820 von sneakee am 22.12.20 12:38:31http://ir.soligenix.com/2020-12-22-Soligenix-Announces-Topli…
Durchsuchen
